Rein Therapeutics Inc. (NASDAQ:RNTX – Free Report) – Stock analysts at HC Wainwright raised their FY2026 EPS estimates for Rein Therapeutics in a research report issued on Tuesday, August 18th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings per share of ($0.47) for the year, up from their previous estimate of ($0.53). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Rein Therapeutics’ current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for Rein Therapeutics’ Q4 2026 earnings at ($0.15) EPS, FY2028 earnings at ($0.67) EPS and FY2029 earnings at ($0.58) EPS.
Several other research firms have also weighed in on RNTX. Wall Street Zen upgraded shares of Rein Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. Weiss Ratings upgraded shares of Rein Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, August 3rd. Finally, Maxim Group assumed coverage on Rein Therapeutics in a report on Monday, July 20th. They set a “buy” rating and a $4.00 price target for the company. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $6.00.
Rein Therapeutics Price Performance
Shares of RNTX stock opened at $0.79 on Thursday. The stock has a market cap of $68.33 million, a P/E ratio of -0.46 and a beta of 1.39. The company has a fifty day moving average price of $0.88 and a two-hundred day moving average price of $1.12. Rein Therapeutics has a one year low of $0.69 and a one year high of $2.18.
Rein Therapeutics (NASDAQ:RNTX – Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.17.
Institutional Investors Weigh In On Rein Therapeutics
Large investors have recently added to or reduced their stakes in the business. Voss Capital LP lifted its holdings in Rein Therapeutics by 59.2% during the 4th quarter. Voss Capital LP now owns 4,243,969 shares of the company’s stock valued at $4,923,000 after purchasing an additional 1,577,437 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Rein Therapeutics by 32.2% in the third quarter. Vanguard Group Inc. now owns 1,168,407 shares of the company’s stock valued at $1,338,000 after purchasing an additional 284,300 shares during the period. Cable Car Capital LP bought a new position in shares of Rein Therapeutics in the second quarter valued at about $588,000. Sigma Planning Corp lifted its stake in shares of Rein Therapeutics by 41.0% during the 1st quarter. Sigma Planning Corp now owns 348,677 shares of the company’s stock worth $453,000 after buying an additional 101,400 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Rein Therapeutics by 15.1% during the 4th quarter. Geode Capital Management LLC now owns 284,555 shares of the company’s stock worth $330,000 after buying an additional 37,244 shares during the last quarter. Institutional investors own 90.89% of the company’s stock.
Rein Therapeutics Company Profile
Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.
The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.
Read More
- Five stocks we like better than Rein Therapeutics
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Rein Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rein Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
